
Annual report 2025
added 02-12-2026
Envista Holdings Corporation Cash Flow 2011-2026 | NVST
Annual Cash Flow Envista Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
276 M | 336 M | 276 M | 183 M | 362 M | 284 M | 398 M | 400 M | 359 M | - | - | - | - | - | - |
Depreciation & Amortization |
116 M | 123 M | 136 M | 138 M | 118 M | 122 M | 120 M | 130 M | 121 M | - | - | - | - | - | - |
Accounts Payables |
192 M | 175 M | 180 M | 228 M | 186 M | 235 M | 208 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
430 M | 363 M | 408 M | 394 M | 332 M | 361 M | 444 M | - | - | - | - | - | - | - | - |
Total Inventories |
288 M | 241 M | 259 M | 301 M | 264 M | 267 M | 278 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Envista Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 300 K | - | - | - | 40.3 M | - | - | - | 3.1 M | - | 72.4 M | - | 3.5 M | - | 226 M | - | 16.6 M | - | 90.5 M | -57.6 M | -62.3 M | - | 210 M | 113 M | -9 M | - | 210 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
29.8 M | 27.9 M | - | - | 34 M | 32.1 M | - | - | - | 8.5 M | - | 23.9 M | - | 7.8 M | - | 29.4 M | - | 10.3 M | - | 31.5 M | 19.6 M | 9.5 M | - | 29.8 M | 19.8 M | 9.8 M | - | 29.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
172 M | 164 M | 175 M | 172 M | 172 M | 175 M | 180 M | 169 M | 177 M | 187 M | 228 M | 190 M | - | 181 M | 186 M | 171 M | 209 M | 205 M | 202 M | 202 M | 235 M | 235 M | 208 M | 208 M | 208 M | 208 M | 217 M | 217 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
423 M | 393 M | 363 M | 392 M | 381 M | 413 M | 408 M | 417 M | 415 M | 402 M | 394 M | 392 M | - | 343 M | 332 M | 307 M | 355 M | 358 M | 302 M | 302 M | 361 M | 361 M | 444 M | 444 M | 444 M | 444 M | 460 M | 460 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
282 M | 261 M | 241 M | 266 M | 264 M | 267 M | 259 M | 279 M | 297 M | 307 M | 301 M | 291 M | - | 280 M | 264 M | 274 M | 312 M | 283 M | 216 M | 216 M | 267 M | 267 M | 278 M | 278 M | 278 M | 278 M | 279 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Envista Holdings Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
$ 70.49 | 0.36 % | $ 14 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.13 | -3.93 % | $ 228 M | ||
|
ICU Medical
ICUI
|
$ 129.4 | -0.41 % | $ 3.19 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
LeMaitre Vascular
LMAT
|
$ 109.99 | 1.97 % | $ 2.49 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 10.5 | -0.94 % | $ 25.5 M | ||
|
Masimo Corporation
MASI
|
$ 178.69 | 0.14 % | $ 9.52 B | ||
|
Merit Medical Systems
MMSI
|
$ 67.55 | -0.85 % | $ 4 B | ||
|
Nephros
NEPH
|
$ 3.05 | -1.93 % | $ 31.7 M | ||
|
Haemonetics Corporation
HAE
|
$ 56.66 | -3.08 % | $ 2.85 B | ||
|
Baxter International
BAX
|
$ 16.72 | 0.57 % | $ 8.58 B | ||
|
Pro-Dex
PDEX
|
$ 49.99 | 4.25 % | $ 164 M | ||
|
Pulse Biosciences
PLSE
|
$ 21.29 | 1.72 % | $ 1.43 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
OraSure Technologies
OSUR
|
$ 3.06 | -0.65 % | $ 225 M | ||
|
AngioDynamics
ANGO
|
$ 10.63 | -0.75 % | $ 434 M | ||
|
Intuitive Surgical
ISRG
|
$ 471.91 | -1.28 % | $ 168 B | ||
|
AtriCure
ATRC
|
$ 29.61 | -0.57 % | $ 1.41 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.69 | 0.94 % | $ 200 M | ||
|
iRhythm Technologies
IRTC
|
$ 118.69 | 0.47 % | $ 3.8 B | ||
|
BioLife Solutions
BLFS
|
$ 19.7 | 2.76 % | $ 908 M | ||
|
Repligen Corporation
RGEN
|
$ 116.3 | -0.04 % | $ 6.48 M | ||
|
Milestone Scientific
MLSS
|
$ 0.29 | 3.78 % | $ 23.1 M | ||
|
electroCore
ECOR
|
$ 6.17 | 0.65 % | $ 52.3 K | ||
|
ResMed
RMD
|
$ 228.19 | 0.1 % | $ 33.3 B | ||
|
Retractable Technologies
RVP
|
$ 0.72 | -0.04 % | $ 21.6 M | ||
|
Glaukos Corporation
GKOS
|
$ 105.23 | -1.51 % | $ 5.1 B | ||
|
Microbot Medical
MBOT
|
$ 2.5 | -0.79 % | $ 25.5 M | ||
|
STAAR Surgical Company
STAA
|
$ 18.97 | 2.49 % | $ 940 M | ||
|
STERIS plc
STE
|
$ 221.73 | 0.33 % | $ 21.9 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Stereotaxis
STXS
|
$ 1.8 | -2.17 % | $ 164 M | ||
|
Teleflex Incorporated
TFX
|
$ 106.56 | 0.67 % | $ 4.75 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 155.92 | -0.19 % | $ 44.9 B | ||
|
Repro Med Systems
KRMD
|
$ 4.4 | -0.68 % | $ 203 M | ||
|
Utah Medical Products
UTMD
|
$ 63.8 | -2.04 % | $ 232 M | ||
|
West Pharmaceutical Services
WST
|
$ 245.27 | 1.6 % | $ 17.7 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.47 | -0.65 % | $ 2.29 B | ||
|
Alcon
ALC
|
$ 74.24 | 0.13 % | $ 40.4 B |